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that effective treatment includes antipsychotic medications combined with psychoeducational,
psychotherapeutic, and educational interventions. Since this Practice Parameterwas last published
in 2001, several controlled trials of atypical antipsychotic agents for early-onset schizophrenia have
been conducted. However, studies suggest thatmany youthwith early-onset schizophrenia do not
respondadequately to available agents andarevulnerable to adverse events, particularlymetabolic
side effects. Further research is needed todevelopmore effective and safer treatments. J.Am.Acad.
Child Adolesc. Psychiatry, 2013;52(9):976–990. Key Words: schizophrenia, psychosischizophrenia portends substantialmorbidity
and suffering to those afﬂicted and theirS families. Schizophrenia spectrum disorders
often ﬁrst present during adolescence and rarely in
childhood. Since the last Practice Parameter for the
Assessment and Treatment of Children and
Adolescents with Schizophrenia was published,1
knowledge of this topic has increased substan-
tially. This revisedversionof theparameterpresents
the most up-to-date research ﬁndings and clinical
standards regarding the assessment and treatment
of this disorder.
METHODOLOGY
Earlier versions of this parameter were published
in 1994 and 2001. The most recent literature search
covered a 5-year period (January 2004 through
August 2010) using PubMed, PsycInfo (Ovid),
CINAHL (EBSCO), andWeb of Science databases.
The initial searcheswere inclusive and sensitive for
PubMed using a combination of MeSH headings
and key words. The search was adjusted for
CINAHL and PsycInfo by “translating,” where
necessary, from the MeSH thesaurus to the
CINAHL and PsycInfo thesauri, and using the
same key words. The Web of Science search also
was adjusted because this database responds only
to key-word searching.JOURN
www.jaacap.orgIn PubMed, the search strategy from the
Cochrane Review Group on schizophrenia was
used (see below), yielding 282,328 results. This was
reﬁned to reﬂect treatment studies and reviews
with limits for ages 0 to 18 years and English
language applied, resulting in 3,662 articles. Search
in CINAHL yielded an additional 55 articles, Web
ofScience 214articles, andPsycInfo24articles.Once
duplicates were removed, there were 3,186 articles.
The titles and abstracts of these articles were
reviewed. Many studies identiﬁed in the search
were conducted in a primarily adult population
with only a few adolescent subjects. Articles with a
focus on early-onset schizophrenia (EOS) treatment
(87) were prioritized for inclusion. Additional
selection criteria were based on the study’s weight
in the hierarchy of evidence (e.g., randomized
controlled trials), attending to the quality of indi-
vidual studies and the generalizability to clinical
practice. The search was augmented by review of
articles published before 2004, those nominated by
expert review, those recently accepted for publica-
tion inpeer-reviewed journals, and thosepertaining
to adult-onset schizophrenia treatment.
Search terms (this search statement was
modeled after the Cochrane Review Group on
Schizophrenia Specialised Register search strate-
gies originally designed for the OVID database,AL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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thisia OR neuroleptic OR neuroleptics OR neuro-
leptic* OR parkinsonian* OR psychoses OR
psychotic OR psychosis OR schizoaffective OR
schizophren* OR tardive OR “childhood onset
schizophrenia”OR“earlyonset schizophrenia”OR
((chronic OR paranoid) AND schizophren*) OR
“Akathisia, Drug-Induced” [MeSH] OR “Dyski-
nesia, Drug-Induced” [MeSH] OR “Psychoses,
Substance-Induced” [MeSH] OR (“Antipsychotic
Agents” [MeSH] OR “Catatonia” [MeSH]) OR
“Neuroleptic Malignant Syndrome” [MeSH] OR
“Parkinsonian Disorders” [MeSH] OR “Schizo-
phrenia and Disorders with Psychotic Features”
[MeSH] OR “Schizophrenia, Childhood”[MeSH].
DEFINITIONS
EOS is deﬁned as onset before 18 years of age.
Onset before 13 years of age is often described as
childhood-onset schizophrenia (COS). The diag-
nosis of schizophrenia in children and adoles-
cents is made using the same criteria as in adults,
following the criteria outlined by the DSM-52 or
International Classiﬁcation of Diseases, 10th Revi-
sion.3 The DSM-5 requires that two or more
characteristic symptoms, i.e., hallucinations,
delusions, disorganized speech, disorganized or
catatonic behavior, and/or negative symptoms,
must be present for at least 1 month (or shorter if
successfully treated). During this active phase,
hallucinations, delusions, or disorganized speech
must be present. Evidence of the disorder must be
present for at least 6 months and must be asso-
ciated with a signiﬁcant decline in social or
occupational functioning. In children and
adolescents, decline in function may include the
failure to achieve age-appropriate levels of inter-
personal or academic development. The Interna-
tional Classiﬁcation of Diseases, 10th Revision
diagnostic criteria are similar to the DSM-5
criteria except that the total duration of illness
required is at least 1 month.
Schizophrenia as deﬁned by the DSM-5 differs
from the DSM-IV-TR4 by the following: delusions,
hallucinations, or disorganized speech are required
for diagnosis and commenting and conversing
hallucinations and bizarre delusions are no
longer accorded special diagnostic status.
BRIEF HISTORY
Descriptions of madness and insanity date to
antiquity. In the early 20th century, Kraeplin
characterized two forms of insanity, manic-JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATR
VOLUME 52 NUMBER 9 SEPTEMBER 2013depressive illness and dementia praecox.5 Bleu-
ler substituted the term schizophrenia (splitting of
the mind) for dementia praecox,6 given the obser-
vation that the illness was not associated with
dementia, but rather with the loss of association
of thought processes and the disruption of
thought, emotions, and behavior.7
The original descriptions of the disorder
recognized a typical pattern of onset during
adolescence and young adulthood, with reports
of rare cases in children. However, beginning
with the works of Bender, Kanner, and others,8
the concept of childhood schizophrenia was
broadened to include syndromes deﬁned by de-
velopmental lags in the maturation of language,
perception, and motility (which also included
infantile autism).9 Hallucinations and delusions
were not required criteria. This nosology was
adopted by the DSM-II. As a result, the childhood
schizophrenia literature from this period overlaps
with that of autism and other pervasive devel-
opmental disorders.
Seminal work by Kolvin10 and Rutter11 estab-
lished the distinctiveness of the various child-
hood psychoses and the similarity between child
and adult schizophrenia. Therefore, beginning
with the DSM-III, the diagnosis of schizophrenia
in youth has been made using the same criteria as
for adults, regardless of age of onset. Subsequent
research has generally validated this decision.
EPIDEMIOLOGY
The worldwide prevalence of schizophrenia is
generally held to be approximately 1%, with
some variation noted across studies and pop-
ulations. The male-to-female ratio is approxi-
mately 1.4 to 1.12
The prevalence of EOS has not been
adequately studied. Onset before 13 years of age
appears to be quite rare. The rate of onset then
increases during adolescence, with the peak ages
of onset for the disorder ranging from 15 to 30
years. EOS tends to occur more often in male
individuals. As age increases, this ratio tends to
even out. The diagnostic validity of schizophrenia
in young children, e.g., younger than 6 years, has
not been established.
CLINICAL PRESENTATION
Psychosis is deﬁned as the severe disruption of
thought and behavior resulting in the loss of
reality testing. The diagnosis of psychosis is
based on overt changes in a person’s behaviorY
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thinking evident on mental status examination.13
Although psychotic symptoms are characteristic
of schizophrenia, psychosis may present with
other illnesses, including mood disorders, neu-
rologic conditions, and acute intoxication.
The diagnostic assessment of schizophrenia in
youth presents unique developmental concerns.
Misdiagnosis is common, particularly at time of
onset.14-17 Conditions often misdiagnosed as
schizophrenia in youth include bipolar disorder
and other psychotic mood disorders,17,18 person-
ality disorders,19 obsessive-compulsive disorder,20
and developmental syndromes.16 Comprehensive
diagnostic assessments, which reconcile mental
status ﬁndings with the rigorous application of
diagnostic criteria, help improve accuracy.14,21
Most children who report hallucinations do
not meet criteria for schizophrenia, and many do
not have a psychotic illness.22,23 Normative child-
hood experiences, including overactive imagina-
tions and vivid fantasies, can be misinterpreted as
psychosis. Distinguishing formal thought disorder
from developmental disorders that impair speech
and language function can be a challenge.24
Expertise in childhood psychopathology and
experience in assessing reports of psychotic
symptoms in youth are important prerequisite
skills for clinicians evaluating youth for possible
psychosis.
Symptomatology
Schizophrenia is characterized by positive and
negative symptoms. Positive symptoms refer to
hallucinations, delusions, and thought disorder.
Negative symptoms are those of deﬁcits, i.e., ﬂat
affect, anergy, and paucity of speech or thought.
Disorganized behavior may represent an inde-
pendent third domain, including disorganized
speech (e.g., incoherence, looseness of associa-
tions), bizarre behavior, and poor attention.4
Hallucinations, thought disorder, and ﬂattened
affect have been consistently found in EOS,
whereas systematic delusions and catatonic
symptoms occur less frequently.25 Developmental
variation in language and cognition may affect the
range and quality of symptom presentation.
Cognitive Delays
Cognitive delays are common with EOS.26 Deﬁ-
cits in memory, executive functioning, attention,
and global impairments are generally noted.
Children who later develop schizophrenia often
have premorbid problems with verbal reasoning,JOURN
978 www.jaacap.orgworking memory, attention, and processing
speed.27 Cognitive decline typically occurs at the
time of onset of illness. Once established, intel-
lectual deﬁcits appear to be stable over time
without continued deterioration.28 These ﬁndings
are consistent with those in the adult literature.
Premorbid Functioning
Premorbid abnormalities are evident in most
youth who develop schizophrenia, especially
those with COS.29 Common premorbid difﬁcul-
ties include social withdrawal and isolation,
disruptive behavior disorders, academic difﬁcul-
ties, speech and language problems, and cogni-
tive delays. Because schizophrenia in youth often
has an insidious onset, the gradual development
of psychotic symptoms in a child with premorbid
language delays and social withdrawal can be
difﬁcult to recognize.
Predicting which youth with premorbid char-
acteristics of schizophrenia will eventually de-
velop the disorder remains a challenge. Factors in
high-risk youth that predict progression into the
illness include familial risk for schizophrenia plus
a recent deterioration in functioning; unusual,
suspicious, or paranoid thought content; greater
social impairment; and/or a history of substance
abuse.30
ETIOLOGY
Schizophrenia is a heterogeneous disorder with
multiple etiologies. To date, no single set of causes
has been identiﬁed. Current evidence suggests
that a multifactorial neurodevelopmental model
best explains the development of schizophrenia,
with multiple genetic and environmental expo-
sures playing roles.31 Neurobiological research
suggests that EOS and adult-onset schizophrenia
share etiologic factors, although EOS may be
a more severe form.32,33
Genetic Factors
Family, twin, and adoption studies support
a strong genetic component for schizophrenia.
The lifetime risk of developing the illness is 5 to
20 times higher in ﬁrst-degree relatives of affected
probands compared with the general population.
The rate of concordance between monozygotic
twins is approximately 40% to 60%. Concordance
rates in dizygotic twins and other siblings are
5% to 15%.34 Genomewide association studies,
using large collaborative international cohorts,
have published ﬁndings implicating differentAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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histocompatibility complex (6p21.1), MIR137, and
ZNF804a.35,36 For EOS, positive associations have
been reported for several candidate genes, in-
cluding those reported in the adult literature.37
Emerging evidence shows that rare deletions
and duplications are enriched in individuals with
schizophrenia.38-42 Structural mutations arising at
genomic “hotspots,” including 1q21.1, 15q13.3,
and 22q11.2, may be responsible for 0.5% to 1.0%
of cases. EOS appears to be associated with
a higher rate of large cytogenetic abnormalities
and rare structural variants37 than reported in
adults with the illness. These include 22q11.2
deletion syndrome (velocardiofacial syndrome),43
which is associated with substantial rates of
behavioral, cognitive, and psychiatric problems,
including psychosis. Most rare copy number
errors detected in affected persons are found at
different genetic loci, and many are unique to one
individual or family. Thus, the emerging research
suggests that most affected persons have a
different genetic cause, which has important
implications for intervention and translational
research.44
Environmental Exposures
Genetic and environmental factors interact to
shape neurodevelopmental processes, affecting
disease risk and progression.45 Environmental
exposures may mediate disease risk by different
mechanisms, including direct neurologic damage,
gene-by-environment interactions, epigenetic ef-
fects, and/or de novo mutations.46 Numerous
environmental factors have been hypothesized to
contribute to the development of schizophrenia,
including in utero exposure to maternal famine,
paternal age, prenatal infections, obstetric com-
plications, marijuana use, and immigration.47
Neuroanatomic Abnormalities
Structural brain aberrations most consistently re-
ported in adults with schizophrenia include
increased lateral ventricle volumes and decreases
in hippocampus, thalamus, and frontal lobe
volumes.48 EOS is associated with similar abnor-
malities,49,50 with limbic structures appearing to
play a particularly important role.51 Youth with
EOS exhibit signiﬁcant decreases in gray matter
volumes52,53 and decreased cortical folding.54
Cortical abnormalities appear to be most pro-
found in COS.55 Follow-up longitudinal studies
have shown that cortical thinning in COS may
plateau in early adulthood, when it becomesJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATR
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brain ﬁndings found in EOS are theorized to stem
from the disruption of neurodevelopmental pro-
cesses emerging during adolescence.58 In the
National Institute of Mental Health COS cohort,
unaffected siblings of patients shared similar
patterns of cortical deﬁcits, suggesting these are
familial traits with variable impact on disease
risk.59,60
Psychological and Social Factors
There is no evidence that psychological or social
factors cause schizophrenia. Rather, environ-
mental factors may potentially interact with bio-
logic risk factors to mediate the timing of onset,
course, and severity of the disorder.61 Psychoso-
cial factors, including expressed emotion within
the family setting, inﬂuence the onset and/or
exacerbation of acute episodes and relapse rates.
These interactions are complex and bidirectional.
Being raised in a healthy home environment may
be protective for children with a familial risk for
schizophrenia.62 Alternatively, the presence of
difﬁcult family interactions may not be causal,
but rather a reaction to the collection of difﬁcul-
ties the patient brings to the family setting.COURSE AND OUTCOME
The course of schizophrenia varies across indi-
viduals. There are hallmark phases that are
important to recognize when making diagnostic
and therapeutic decisions.
Prodrome. Most patients experience some
degree of functional deterioration before the
onset of psychotic symptoms, including social
withdrawal and isolation, idiosyncratic or bizarre
preoccupations, unusual behaviors, academic
failure, deteriorating self-care skills, and/or
dysphoria. These changes may be associated with
depression, anxiety, aggressive behaviors, or
other conduct problems, including substance
abuse, which often confuse the diagnostic picture.
The prodromal phase may vary from an acute
marked change in behavior to a chronic insidious
deterioration.
Acute Phase. The acute phase is marked by
prominent positive symptoms (i.e., hallucinations,
delusions, disorganized speech and behavior) and
a signiﬁcant deterioration in functioning. This
phase may last several months depending in part
on the response to treatment.
Recuperative/Recovery Phase. After the acute
phase, with the remission of the acute psychosis,Y
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the patient continues to experience a signiﬁcant
degree of impairment. Negative symptoms (ﬂat
affect, anergia, social withdrawal) predominate,
although some positive symptoms may persist. In
addition, some patients will develop a post-
psychosis depression characterized by dysphoria.
Residual Phase. Youth with EOS may have pro-
longed periods (several months or more) between
acute phases when they do not experience signiﬁ-
cant positive symptoms. However, most patients
will continue to be at least somewhat impaired
owing to negative symptoms. Unfortunately,
some affected individuals never progress to
residual symptoms and remain chronically
symptomatic despite adequate treatment.
Outcome
Follow-up studies of EOS, spanning periods up to
several decades, have suggested moderate to
severe impairment across the lifespan.25 Poor
long-term outcome is predicted by low premorbid
functioning, insidious onset, higher rates of
negative symptoms, childhood onset, and low
intellectual functioning.15,63-67 When followed
into adulthood, youth with EOS have shown
greater social deﬁcits, lower levels of employment,
and a lower likelihood to live independently
compared with those with other childhood-onset
psychotic disorders.67,68
Suicidality is prevalent in youth with schizo-
phrenia spectrum disorders.69 In follow-up stud-
ies, at least 5% of individuals with EOS died by
completed suicide or by accidental death directly
because of behaviors inﬂuenced by psychotic
thinking.17,70 As adults, individuals with schizo-
phrenia are at higher risk of othermorbidities, such
as heart disease, obesity, human immunodeﬁ-
ciency virus, hepatitis, and diabetes.71DIFFERENTIAL DIAGNOSIS
The effective treatment of schizophrenia relies on
an accurate diagnosis and a thorough assessment
to identify any other contributing medical or
psychiatric conditions and/or psychosocial
stressors. The proper assessment of psychosis in
youth requires the gauging of potential symptom
reports in the context of normal development.
The mere fact that a child responds afﬁrmatively
to questions regarding hallucinations or delu-
sions does not ipso facto mean the child is
psychotic. Psychotic symptoms occur in the
context of an illness, and psychotic illnesses areJOURN
980 www.jaacap.orgrare in youth, especially in children younger than
12 years. The accurate diagnosis of schizophrenia
and other psychotic illnesses should be based
on characteristic patterns of illness and overt
signs on the mental status examination. Clinical
features that help conﬁrm a diagnosis of schizo-
phrenia include deteriorating function, thought
disorder, and bizarre behavior. There are several
important diagnoses to rule out when assessing
a youth for schizophrenia.
Medical Conditions
The list of medical conditions that can result in
psychosis is exhaustive, including central nervous
system infections, delirium, neoplasms, endocrine
disorders, genetic syndromes (e.g., velocardiofacial
[22q11] syndrome), autoimmune disorders, and
toxic exposures.
Drugs of abuse that can result in psychotic
symptoms include dextromethorphan, lysergic
acid diethylamide, hallucinogenic mushrooms,
psilocybin, peyote, cannabis, stimulants, and
inhalants. Prescription drugs associated with
psychosis, especially when used inappropriately,
include corticosteroids, anesthetics, anticholiner-
gics, antihistamines, and amphetamines. Typi-
cally, acute psychosis secondary to intoxication
resolves within days to weeks once the offending
drug is discontinued.
Adolescents with EOS appear to be at substan-
tial risk for comorbid substance abuse.72 Cannabis
use in teenagers is associated with a higher risk of
eventually developing psychosis.73 When drug
abuse precedes the development of schizophrenia,
it is difﬁcult to gauge whether the psychosis
represents independent drug effects or the
unmasking of the underlying illness in an indi-
vidual with other neurobiological vulnerabilities.
Schizoaffective Disorder
By deﬁnition, schizoaffective disorder requires
the presence of psychotic symptoms plus prom-
inent mood episodes (meeting full criteria for
mania or depression) that are present for
a substantial duration of the illness. The DSM-5
emphasizes the requirement of a full mood
episode, which should be present for the majority
of the total duration of the active and residual
portions of the illness. These are important
distinctions because mood symptoms, such as
dysphoria, irritability, or grandiosity, are com-
mon in individuals with schizophrenia, and the
reliability of the diagnosis of schizoaffective
disorder in clinical settings has been poor.AL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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with the same severity of psychotic symptoms
and functional impairment as those with schizo-
phrenia.74 The stability of early-onset schizo-
affective disorder as a diagnosis appears to vary
over time and can be difﬁcult to distinguish from
schizophrenia.15,21
Affective Psychosis
Psychotic mood disorders (especially bipolar
disorder) can present with different affective and
psychotic symptoms. Full-blown mania in teen-
agers often presents with ﬂorid psychosis, in-
cluding hallucinations, delusions, and thought
disorder.75 Psychotic depression may present
with mood congruent or incongruent hallucina-
tions or delusions.76
Alternatively, symptoms of schizophrenia,
such as negative symptoms, may be confused
with a mood disorder. The overlap in symptoms
increases the likelihood of misdiagnosis. Longi-
tudinal reassessment is needed to ensure diag-
nostic accuracy.
Atypical Reports of Psychotic Symptoms
Many children and adolescents report symptoms
suggestive of hallucinations and delusions, yet do
not present with overt evidence of psychosis.22,23,77
In an epidemiologic survey, questions regarding
possible psychotic symptoms had a high rate of
false-positive results.78 Reports suggestive of
psychosis in children may stem from overactive
imaginations, cognitive limitations, or simply
misunderstanding the question.
Youth diagnosed with posttraumatic stress
disorder, conduct problems, and/or depression
havebeen found to report signiﬁcantly higher rates
of psychotic-like symptoms than controls.22,23,77
Maltreated youth are particularly vulnerable to
report such symptoms, which may represent
dissociation and/or anxiety, including intrusive
thoughts/worries, derealization, or depersonal-
ization.15,79-81 Individuals with childhood abuse
histories are at greater risk for being diagnosed
with psychotic illnesses as adults.82,83 Of course,
individuals with schizophrenia may have signiﬁ-
cant histories of trauma. A trauma history neither
establishes nor rules out a schizophrenia spectrum
disorder. The clinical task is to determine the
nature of symptom reports to make an accurate
diagnostic assessment. Differentiating trauma-
related symptoms from true psychosis can be
particularly challenging, yet has important impli-
cations for treatment and diagnostic speciﬁcity.84JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATR
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Autism and pervasive developmental disorders
are distinguished from schizophrenia by the
absence of psychotic symptoms and by the
predominance of the characteristic deviant
language patterns, aberrant social relatedness, or
repetitive behaviors. The younger age of onset
and the absence of a normal period of develop-
ment are also indicative. The premorbid abnor-
malities in EOS tend to be less pervasive and
severe than those with autism.10,11
Youth with schizophrenia often have pre-
morbid and/or comorbid problems with social
oddities and aloofness, which may be character-
ized as autism spectrum disorders.85 These
symptoms are likely nonspeciﬁc markers of dis-
rupted brain development86 and may reﬂect
potential shared etiologic mechanisms that are
common to both syndromes.85 Once psychotic
symptoms become apparent, the diagnosis of
schizophrenia takes precedence.EVIDENCE BASE FOR PRACTICE
PARAMETERS
In this parameter, recommendations for best
assessment and treatment practices are stated in
accordance with the strength of the underlying
empirical and/or clinical support.
 Clinical Standard [CS] is applied to recom-
mendations that are based on rigorous empir-
ical evidence (e.g., meta-analyses, systematic
reviews, individual randomized controlled
trials) and/or overwhelming clinical consensus
 Clinical Guideline [CG] is applied to recom-
mendations that are based on strong empirical
evidence (e.g., nonrandomized controlled trials,
cohort studies, case-control studies) and/or
strong clinical consensus
 Clinical Option [OP] is applied to recommen-
dations that are based on emerging empirical
evidence (e.g., uncontrolled trials or case
series/reports) or clinical opinion, but lack
strong empirical evidence and/or strong clin-
ical consensus
 Not Endorsed [NE] is applied to practices that
are known to be ineffective or contraindicated
The strength of the empirical evidence is rated
in descending order as follows:
 Randomized, Controlled Trial [rct] is applied to
studies in which subjects are randomly as-
signed to two or more treatment conditionsY
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which subjects are nonrandomly assigned to
two or more treatment conditions
 Uncontrolled Trial [ut] is applied to studies in
which subjects are assigned to one treatment
condition
 Case series/report [cs] is applied to a case
series or a case reportRECOMMENDATIONS
Recommendation 1. Psychiatric assessments for
children and adolescents should include
screening questions for psychosis. [CS]
In the psychiatric assessment, general inquiries
should be made regarding changes in behavior or
any evidence of problems with thinking or
perceptions. Questions such as “Does your mind
ever play tricks on you?,” “Do you hear voices
talking to you when no one is there?,” and “Does
your mind ever feel confused” help elicit possible
symptoms. Youthwith EOS can generally describe
relevant aspects of their psychotic symptoms,
although somewill be too disorganized, confused,
and/or paranoid to provide accurate details or
relevant history. Parents, family members,
teachers, and treatment providers are important
sources of information for documenting overt
changes in behavior and thinking.
It is important to gauge suspected psychosis in
a developmental context. When evaluating youth,
especially children younger than 12 years, the
clinician must ensure that the child understands
the question and that developmental consider-
ations are taken into account. True psychotic
symptoms are generally confusing to the indi-
vidual and experienced as distressing external
phenomena beyond the individual’s control.
Highly descriptive, detailed, organized, and/or
situation-speciﬁc reports are less likely to repre-
sent true psychosis. Schizophrenia and other
psychotic illnesses are associated with disorga-
nized thinking and behavior and deterioration in
functioning. Overt signs of the illness should be
evident on the mental status examination and in
descriptions of the child’s behavior. Without
overt evidence of psychosis, the validity of
symptom reports suggestive of schizophrenia in
children needs to be carefully scrutinized.
Recommendation 2. The diagnosis of
schizophrenia in children and adolescents
should follow DSM-5 criteria, using the same
criteria as for adults. [CS]JOURN
982 www.jaacap.orgA comprehensive diagnostic assessment in-
cludes interviews with the child or adolescent
and the family plus a review of past records and
any other available ancillary information. Issues
to address include overt evidence of psychotic
symptoms (including mental status examination
ﬁndings, symptom presentation, course of illness)
and a pertinent review of systems and potential
confounding factors (including any history of
signiﬁcant developmental problems, mood
disorders, trauma, or substance abuse).
Diagnostic accuracy may be improved by
using a structured diagnostic interview that is
designed for youth and includes a module for
psychotic illnesses.87 Diagnostic status should be
reassessed over time because clinical presenta-
tions of psychotic illnesses tend to change, espe-
cially during the ﬁrst few years of illness.88 In
some cases, decreasing a child’s medication
burden (including attempting a medication-free
trial if possible) may be indicated to clarify
a complicated clinical presentation.
Recommendation 3. Youth with suspected
schizophrenia should be carefully evaluated for
other pertinent clinical conditions and/or asso-
ciated problems, including suicidality, comor-
bid disorders, substance abuse, developmental
disabilities, psychosocial stressors, and medical
problems. [CS]
Youth with suspected schizophrenia require
a thorough psychiatric and medical evaluation,
including the assessment for common comorbid
conditions, such as substance abuse or cognitive
delays. When present, active psychotic symptoms
are generally prioritized as the main target for
treatment. Comorbid conditions, such as sub-
stance abuse,may respondbetter to treatment once
acute symptoms of schizophrenia are stabilized.
However, any life-threatening symptoms, such as
suicidal behavior or severe aggressive behaviors,
must be prioritized in the treatment plan.
There are no neuroimaging, psychological, or
laboratory tests that establish a diagnosis of
schizophrenia. The medical evaluation focuses on
ruling out nonpsychiatric causes of psychosis and
establishing baseline laboratory parameters for
monitoring medication therapy. More extensive
evaluation is indicated for atypical presentations,
such as a gross deterioration in cognitive and
motor abilities, focal neurologic symptoms, or
delirium.
Assessments are obtained based on speciﬁc
medical indications, e.g., neuroimaging studiesAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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electroencephalogram for a clinical history sug-
gestive of seizures. Toxicology screens are indi-
cated for acute onset or exacerbations of
psychosis when exposure to drugs of abuse
cannot otherwise be ruled out. Genetic testing is
indicated if there are associated dysmorphic or
syndromic features. Similarly, tests to rule out
speciﬁc syndromes or diseases (e.g., amino acid
screens for inborn errors of metabolism, cerulo-
plasmin for Wilson disease, porphobilinogen for
acute intermittent porphyria) are indicated for
clinical presentations suggestive of the speciﬁc
syndrome in question. Broad screening for rare
medical conditions is not likely to be informative
in individuals with psychosis who do not present
with other neurologic or medical concerns.
At the time of ﬁrst diagnosis, routine labora-
tory testing typically assesses blood counts, liver
and renal functions, and metabolic parameters
and thyroid functions, which provide a general
medical screen and serve as baseline assessments
for medication monitoring. Neuropsychological
testing cannot be used to establish the diagnosis
but may be important for documenting cognitive
deﬁcits and for treatment and academic planning.
Recommendation 4. Antipsychotic medica-
tion is a primary treatment for schizophrenia
spectrum disorders in children and adoles-
cents. [CS]
The efﬁcacy of antipsychotic medications in the
acute treatment of adultswith schizophrenia iswell
established.89 In community settings, the atypical
agents are often considered the preferred treatment.
However, large adult trials, including the Clinical
Antipsychotic Trials of Intervention Effectiveness
study,90[rct] the Cost Utility of the Latest Antipsy-
chotic Drugs in Schizophrenia study,91[rct] and the
European First-Episode Schizophrenia Trial
study,92[rct] raise questions as to whether second-
generation (atypical) antipsychotics truly have
superior efﬁcacy than ﬁrst-generation (typical)
antipsychotics. Furthermore, many patients do not
maintain the samemedication treatment long term,
often owing to lack of efﬁcacy, side effects, or
noncompliance.
Antipsychotic agents are also considered
ﬁrst-line treatment for schizophrenia spectrum
disorders in youth, with second-generation agents
typically being the treatments of ﬁrst choice.93 It is
recommended that these agents are used in
conjunction with psychotherapeutic interventions
(Recommendation 9).JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATR
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for EOS have been conducted, although all have
limitations and more studies are needed. Older
studies support the use of loxapine94[rct] and hal-
operidol.95[rct] For adolescents with EOS, industry-
sponsored randomized controlled acute trials
support the efﬁcacy of risperidone (n ¼ 257)96[rct]
and aripiprazole (n ¼ 302).97[rct] An industry-
sponsored trial found olanzapine to be superior
to placebo on symptom ratings of psychosis
(n ¼ 107). However, the overall response rate for
olanzapine was low (38%) and did not differ
from placebo.98[rct]
There are few studies comparing the efﬁcacy
and safety of different agents for EOS. In youth
with more broadly deﬁned psychotic disorders
(n ¼ 50), olanzapine was maintained signiﬁcantly
longer than risperidone and haloperidol.99[rct] The
proportion of responders at 8 weeks for olanza-
pine (88%), risperidone (74%), and haloperidol
(53%) was not signiﬁcantly different. Sedation,
extrapyramidal side effects (EPSs), and weight
gain were common in all three groups. A small
randomized controlled 6-week trial of adoles-
cents with ﬁrst-onset psychosis (n ¼ 22) found no
signiﬁcant differences in efﬁcacy or tolerability
between risperidone and quetiapine.100[rct] Simi-
larly, an 8-week study of youth with different
psychotic illnesses (n ¼ 30) found no differences
in efﬁcacy among olanzapine, risperidone, and
quetiapine.101[rct]
A national survey ofMedicaid claims from 2001
to 2005 found that approximately 75% of youth
diagnosed with a schizophrenia-related disorder
discontinued their atypical antipsychotic medica-
tion (aripiprazole, risperidone, quetiapine, olan-
zapine, or ziprasidone, N ¼ 1745) within 18
months of initiating treatment.102[cs] Therewere no
differences in rates of treatment discontinuation
or the need for psychiatric hospitalization among
the different agents. A naturalistic follow-up study
of youth with ﬁrst-onset psychosis (n ¼ 109),103[cs]
found that the agents used most often by
providers were risperidone, quetiapine, and
olanzapine. The three agents did not differ in
measurements of symptom decrease. Olanzapine
caused more weight gain, whereas risperidone
was associated with more neurologic side effects.
The Treatment of Early Onset Schizophrenia
Spectrum Disorders Study (TEOSS) compared
olanzapine, risperidone, and molindone for
youth with EOS spectrum disorders, using
a randomized double-blind design. Fewer than
50% of participants (n ¼ 119) responded overY
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signiﬁcant differences found among the treat-
ment groups in response rates or magnitude of
symptom decrease. Patients receiving olanzapine
gained signiﬁcantly more weight than partici-
pants in the other two treatment arms. There
were no statistically signiﬁcant differences in
mean EPS ratings among groups. However, all
patients in the molindone group received
prophylactic benztropine therapy, which likely
inﬂuenced the rate of EPS.
Subjects in the TEOSS who were rated as
responders after 8 weeks of therapy were allowed
to continue their medication for up to an addi-
tional 44 weeks of maintenance treatment. Only
12% of subjects completed 12 months of therapy
on their originally assigned medication.105[rct]
There were no signiﬁcant differences among
molindone, risperidone, and olanzapine in long-
term treatment outcomes. Symptom improve-
ments evident at 8 weeks tended to plateau. Thus,
evidence from the TEOSS suggests that none of
the agents worked sufﬁciently well and all had
potential problems with side effects.
At this time, most atypical and traditional
agents, with the exception of clozapine, can be
used as primary treatment options for EOS. Ris-
peridone, aripiprazole, quetiapine, paliperidone,
and olanzapine are approved by the Food and
Drug Administration for treating schizophrenia in
adolescents 13 years and older. Haloperidol and
molindone are approved by the Food and Drug
Administration for treating schizophrenia in youth
13 years and older. However, the production of
molindonewas discontinued by themanufacturer.
Safety and effectiveness data addressing the use
of antipsychotic medications for EOS remain
limited and for themost part reﬂect short-termuse.
Comparative trials are generally lacking. The
choice of which agent to use ﬁrst is typically based
on Food and Drug Administration approval
status, side effect proﬁle, patient and family pref-
erences, clinician familiarity, and cost. Individual
responses to different antipsychotics are variable,
and if insufﬁcient effects are evident after a 6-week
trial using adequate dosages, a different antipsy-
chotic agent should be tried. The risk for weight
gainwith olanzapinemay limit its use as aﬁrst-line
agent. An industry-sponsored trial of ziprasidone
for adolescents with schizophrenia was termi-
nated prematurely in 2009 because of a lack of
efﬁcacy. Therefore, ziprasidone probably should
not be considered for this population unless other
data supporting efﬁcacy become available.JOURN
984 www.jaacap.orgDepot antipsychotics have not been studied in
pediatric age groups and have inherent risks with
long-term exposure to side effects. Therefore, they
should be considered only in schizophrenic adoles-
cents with documented chronic psychotic symp-
toms and a history of poor medication adherence.
Recommendation 5. Ongoing medication
therapy should be provided to most youth with
schizophrenia to improve functioning and
prevent relapse. [CS]
Most individuals with schizophrenia need
long-term treatment and are at signiﬁcant risk of
relapse if their antipsychotic medication is dis-
continued.89 Most youth with EOS remain chron-
ically impaired, even with treatment.64,66,68,70,105
Patients should maintain regular physician con-
tact to monitor symptom course, side effects, and
adherence. The goal is to maintain the medication
at the lowest effective dose to minimize potential
adverse events. Many youth will continue to expe-
rience some degree of positive or negative symp-
toms, requiring ongoing treatment. The patient’s
overall medication burden should be reassessed
over time, with the goal of maintaining effective
dosages and minimizing side effects. Adjustments
in medications should be gradual, with adequate
monitoring for changes in symptom severity. After
a prolonged remission, a small number of indi-
viduals may be able to discontinue antipsychotic
medications without re-emergence of psychosis.
In these situations, periodic longitudinal moni-
toring is still recommended because some of
these patients may eventually experience another
psychotic episode.
Recommendation 6. Some youth with
schizophrenia spectrum disorders may beneﬁt
from adjunctive medication treatments to
address side effects of the antipsychotic agent
or to alleviate associated symptomatology (e.g.,
agitation, mood instability, depression, explo-
sive outbursts). [CG]
Adjunctive medications commonly used in clin-
ical practice include antiparkinsonian agents
(extrapyramidal side effects),b-blockers (akathisia),
mood stabilizers (mood instability, aggression),
antidepressants (depression, negative symptoms),
and/or benzodiazepines (anxiety, insomnia, aka-
thisia). Benzodiazepines also are used as primary
treatments for catatonia.106 There are no studies
systematically addressing the use of adjunctive
agents in youth with schizophrenia. Although
adjunctive agents are widely used in adults withAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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lish their efﬁcacy.107 Medication trials need to be
conducted systematically to avoid unnecessary
polypharmacy. Although youth with schizo-
affective disorder are often assumed to need
concurrent antidepressants or mood stabilizers,
these practices have not been systematically
studied. In the TEOSS, there were no signiﬁcant
differences in treatment response between patients
with schizophrenia and those with schizoaffective
disorder.104
The u-3 fatty acids have been suggested to be
potentially useful as an adjunctive treatment for
schizophrenia or as preventive therapy.108 One
randomized controlled trial found that u-3 fatty
acids helped delay the onset of psychosis in high-
risk patients.109[rct] As of yet, this study has not
been replicated, and at this time there are no
interventions with conclusive evidence for treat-
ing prodromal psychosis.110
Recommendation 7. A trial of clozapine
should be considered for youth with treatment
resistant schizophrenia spectrum disorders. [CS]
Clozapine is the only antipsychotic agent for
which there is established superiority over other
agents. For treatment-refractory EOS, clozapine
was more beneﬁcial than haloperidol (n ¼ 21) or
high-dose olanzapine (n ¼ 39) for positive and
negative symptoms (n ¼ 21)111[rct],112[rct] and
superior to olanzapine for negative symptoms
(n ¼ 25).113[rct] A naturalistic follow-up study of
EOS found clozapine more effective than halo-
peridol, risperidone, or olanzapine (n ¼ 47).114[cs]
However, owing to potential side effects, cloza-
pine is reserved for treatment refractory cases,
i.e., patients with two or more failed trials of
a ﬁrst-line antipsychotic agent.
Before using clozapine, it is important to
review the child’s clinical status and treatment
history to ensure that the presentation accurately
reﬂects treatment refractory schizophrenia. For
complicated cases or the apparent diagnosis of
schizophrenia in a younger child (e.g., <12 years),
a diagnostic second opinion may be warranted.
When using clozapine, systematic monitoring
of side effects, including following established
protocols for blood count monitoring, is
required. White blood cell and absolute neutro-
phil counts are obtained at baseline and weekly
for the ﬁrst 6 months to monitor the risk for
agranulocytosis. These protocols require a coor-
dinated effort among the pharmacy, laboratory,
and physician to ensure that the blood countJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATR
VOLUME 52 NUMBER 9 SEPTEMBER 2013parameters are being monitored concurrently
with prescriptions.
Recommendation 8. Baseline and follow-up
monitoring of symptoms, side effects, and labora-
tory tests should be performed as indicated. [CS]
Antipsychotic medications need to be moni-
tored systematically for side effects (for speciﬁc
recommendations, see the American Academy
of Child and Adolescent Psychiatry [AACAP]
Practice Parameter for the Use of Atypical
Antipsychotic Medications in Children and
Adolescents).115 When using second-generation
antipsychotic agents, it is particularly important
to monitor metabolic functions and weight gain.
Youth appear to be particularly prone to meta-
bolic side effects, including the long-term risks of
diabetes and hyperlipidemia.
In a naturalistic study, youth naive to antipsy-
chotic therapy (n ¼ 272, 4–19 years old) gained on
average 4.4 kg on aripiprazole, 5.3 kg on risper-
idone, 6.1 kg on quetiapine, and 8.5 kg on olanza-
pine over approximately 12 weeks of treatment.116
Indications for treatment includedpsychosis,mood
disorders, and/or disruptive behavior disorders. A
comparison group of psychiatrically ill youth not
receiving an antipsychotic agent (n ¼ 15) gained
only 0.2 kg over the same time period. Signiﬁcant
increases in cholesterol and/or triglycerides were
noted in subjects taking olanzapine, quetiapine,
and risperidone.
These data highlight the signiﬁcant risk of
weight gain with second-generation agents in
children and adolescents and portend long-term
risks for cardiovascular and metabolic problems.
Thus, it is important that metabolic functions and
risk factors are systematically monitored, in-
cluding body mass index, fasting glucose, fasting
triglycerides, fasting cholesterol, waist circum-
ference, high-density lipoprotein/low-density
lipoprotein, blood pressure, and symptoms of dia-
betes.117 Although the metabolic risks are widely
recognized, most patients taking antipsychotic
medications are not adequately monitored.118
Consensus guidelines recommend the
following119:
 At baseline, assess the patient’s and/or family
history of obesity, diabetes, cardiovascular
disease, dyslipidemia, or hypertension.
 Assess and document the patient’s body mass
index at baseline, at 4, 8, and 12 weeks, and at
least every 3 months thereafter, or more often
as indicated.Y
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glucose, fasting lipid proﬁle, and blood pressure
at baseline and after 3 months of treatment. If
the results are normal after 3 months of treat-
ment, glucose and blood pressure monitoring is
recommended annually. If the lipid proﬁle is
normal after 3 months, follow-up monitoring
is recommended at least every 5 years.
These consensus guidelines were developed
for all age groups. Recommendations for pedi-
atric patients suggest following up on metabolic
parameters every 6 months, with more frequent
monitoring as clinically indicated.120
All patients prescribed antipsychotic agents
should be advised of the importance of a healthy
lifestyle, including cessation of smoking, healthy
diet, and routine exercise.117,120 If a patientdevelops
signiﬁcant weight gain or evidence of metabolic
syndrome (obesity, hypertension, dyslipidemia,
and insulin resistance), the options include switch-
ing to a different antipsychotic agent with lower
metabolic risk or adding an agent that targets
metabolic problems (e.g., metformin).120 Clinically
signiﬁcant abnormalities (e.g., hypercholesterol-
emia) should be targeted for speciﬁc treatment and
may require referral for specialty care.120
EPSs, including dystonia, akathisia, tardive
dyskinesia, and neuroleptic malignant syndrome,
may occur with traditional or atypical agents and
need to be periodically assessed throughout
treatment. Standardized measurements, such as
the Abnormal Involuntary Movement Scale121
and the Neurological Rating Scale,122 are helpful
for monitoring for abnormal movements and
neurologic side effects.
To avoid acute EPSs, the use of prophylactic
antiparkinsonian agents may be considered,
especially in those at risk for acute dystonias or
have a history of dystonic reactions. The need for
antiparkinsonian agents should be re-evaluated
after the acute phase of treatment or if doses are
lowered, because many patients do not need
them during long-term therapy.
Other potential adverse events noted with anti-
psychotic agents include sedation, orthostatic hypo-
tension, sexual dysfunction, hyperprolactinemia,
electrocardiographic changes (including prolonga-
tion of the corrected QT interval), elevated liver
transaminases, and steatohepatitis.93 In adults,
traditional and atypical antipsychotic agents are
associatedwith an increased risk of sudden death.123
Sudden death is very rare in pediatric populations.
However, clinicians should be aware of the potentialJOURN
986 www.jaacap.orgimpact of these agents on cardiac functioning,
including corrected QT interval prolongation, and
monitor appropriately.
Recommendation 9. Psychotherapeutic inter-
ventions should be provided in combination
with medication therapies. [CG]
In adults with schizophrenia, interventions
found to be helpful include cognitive-behavioral
therapies, social skills training, cognitive remedi-
ation, and family interventions. The goals of
treatment include symptom reduction, improving
social/occupational functioning, enhancing qual-
ity of life, and decreasing the risk for relapse.124 In
addition, interventions addressing comorbid
conditions, such as substance abuse, are important
to lower the risk of relapse and improve quality of
functioning.
There are very few studies of psychosocial
treatments for youth with schizophrenia. Psycho-
education, including parent seminars, problem-
solving sessions, milieu therapy (while the
subjects were hospitalized), and networks (reinte-
grating the subjects back into their schools and
communities), was associated with lower rates of
rehospitalization in a small sample of adolescents
with EOS.125[ut] In a separate study, youth who
received cognitive remediation plus psychoeduca-
tional treatment showed greater improvements in
early visual information processing at 1-year
follow-up, although no signiﬁcant short-term im-
provements were found.126[rct],127[rct] A 3-month
trial of cognitive remediation therapy, in compar-
ison with standard therapy, was associated with
improvements in planning ability and cognitive
ﬂexibility in adolescents with schizophrenia.128[rct]
Although further studies are needed, youthwith
EOS should beneﬁt from adjunctive psychother-
apiesdesigned to remediatemorbidity andpromote
treatment adherence. Strategies for the patient
include psychoeducation regarding the illness and
treatment options, social skills training, relapse
prevention, basic life skills training, and problem-
solving skills or strategies. Psychoeducation for
the family is also indicated to increase their under-
standing of the illness, treatment options, and
prognosis and todevelop strategies to copewith the
patient’s symptoms. Some youth will need special-
ized educational programs and/or vocational
training programs to address the cognitive and
functional deﬁcits associated with the illness.
Recommendation 10. Electroconvulsive
therapy may be used with severely impairedAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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cannot be tolerated. [OP]
Research evidence supports the use of electro-
convulsive therapy (ECT), typically in combination
with antipsychotic therapy, as a treatment for
schizophrenia in adults.129 ECT is generally used for
patients who do not adequately respond to or
cannot tolerate antipsychotic medications or those
with catatonia.106 ECT has not been systematically
studied in youth with EOS.130 The clinician must
balance the relative risks and beneﬁts of ECT against
the morbidity of the disorder, the attitudes of the
patient and family, and the availability of other
treatment options. Obtaining informed consent
from the parents, including a detailed discussion
of the potential cognitive deﬁcits, is necessary.PARAMETER LIMITATIONS
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